Comirnaty is still experimental -- the approval is contingent on studies on myocarditis with a 5-year follow-up that will not end until 2-27.
|“||8.4 Pediatric Use Safety and effectiveness of COMIRNATY in individuals 16 through 17 years of age is based on safety and effectiveness data in this age group and in adults [see Adverse Reactions (6) and Clinical Studies (14.1)]. The safety and effectiveness of COMIRNATY in individuals younger than 16 years of age have not been established.||”|
Myocarditis is "predominantly" in males 16 years of age and older. Safety and effectiveness So is not established for those 15 and younger:
|“||Reported cases have occurred predominantly in male adolescents and young adults 16 years of age and older. Onset was typically within several days after mRNA COVID-19 vaccination, and cases have occurred more often after the second dose than the first dose.||”|